Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells

Seiichi Ishizuka, Noriyoshi Kurihara, Daishiro Miura, Kazuya Takenouchi, Jillian Cornish, Tim Cundy, Sakamuri V. Reddy, G. David Roodman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

(23S)-25-Dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647) functions an antagonist of the 1α,25-dihydroxyvitamin D 3 (1α,25-(OH)2D3) nuclear receptor (VDR)-mediated differentiation of human leukemia (HL-60) cells [J. Biol. Chem. 274 (1999) 16392]. We examined the effect of vitamin D antagonist, TEI-9647, on osteoclast formation induced by 1α,25-(OH)2D3 from bone marrow cells of patients with Paget's disease. TEI-9647 itself never induced osteoclast formation even at 10-6 M, but dose-dependently (10-10 to 10-6 M) inhibited osteoclast formation induced by physiologic concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) from bone marrow cells of patients with Paget's disease. At the same time, 10-8 M of TEI-9647 alone did not cause 1α,25-(OH)2D3 dependent gene expression, but almost completely suppressed TAFII-17, a potential coactivator of VDR and 25-hydroxyvitamin D3-24-hydroxylase (25-OH-D3-24- hydroxylase) gene expression induced by 10-10 M 1α,25-(OH) 2D3 in bone marrow cells of patients with Paget's disease. Moreover, TEI-9647 dose-dependently inhibited bone resorption induced by 10-9 M 1α,25-(OH)2D3 by osteoclasts produced by RANKL and M-CSF treatment of measles virus nucleocapsid gene transduced bone marrow cells. These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease.

Original languageEnglish (US)
Pages (from-to)331-334
Number of pages4
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume89-90
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Calcitriol
Osteoclasts
Vitamin D
Bone Marrow Cells
Bone
Cells
Bone Resorption
Gene expression
Gene Expression
Calcifediol
Nucleocapsid
Measles virus
Macrophage Colony-Stimulating Factor
TEI 9647
HL-60 Cells
Cytoplasmic and Nuclear Receptors
Mixed Function Oxygenases
Viruses
Leukemia
Genes

Keywords

  • Bone resorption
  • Coactivator
  • Measles virus
  • Osteoclast
  • Paget's disease
  • Vitamin D antagonist
  • Vitamin D receptor

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells. / Ishizuka, Seiichi; Kurihara, Noriyoshi; Miura, Daishiro; Takenouchi, Kazuya; Cornish, Jillian; Cundy, Tim; Reddy, Sakamuri V.; Roodman, G. David.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 89-90, 05.2004, p. 331-334.

Research output: Contribution to journalArticle

Ishizuka, Seiichi ; Kurihara, Noriyoshi ; Miura, Daishiro ; Takenouchi, Kazuya ; Cornish, Jillian ; Cundy, Tim ; Reddy, Sakamuri V. ; Roodman, G. David. / Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells. In: Journal of Steroid Biochemistry and Molecular Biology. 2004 ; Vol. 89-90. pp. 331-334.
@article{339578e6a7724647b1a3047f28643622,
title = "Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells",
abstract = "(23S)-25-Dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647) functions an antagonist of the 1α,25-dihydroxyvitamin D 3 (1α,25-(OH)2D3) nuclear receptor (VDR)-mediated differentiation of human leukemia (HL-60) cells [J. Biol. Chem. 274 (1999) 16392]. We examined the effect of vitamin D antagonist, TEI-9647, on osteoclast formation induced by 1α,25-(OH)2D3 from bone marrow cells of patients with Paget's disease. TEI-9647 itself never induced osteoclast formation even at 10-6 M, but dose-dependently (10-10 to 10-6 M) inhibited osteoclast formation induced by physiologic concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) from bone marrow cells of patients with Paget's disease. At the same time, 10-8 M of TEI-9647 alone did not cause 1α,25-(OH)2D3 dependent gene expression, but almost completely suppressed TAFII-17, a potential coactivator of VDR and 25-hydroxyvitamin D3-24-hydroxylase (25-OH-D3-24- hydroxylase) gene expression induced by 10-10 M 1α,25-(OH) 2D3 in bone marrow cells of patients with Paget's disease. Moreover, TEI-9647 dose-dependently inhibited bone resorption induced by 10-9 M 1α,25-(OH)2D3 by osteoclasts produced by RANKL and M-CSF treatment of measles virus nucleocapsid gene transduced bone marrow cells. These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease.",
keywords = "Bone resorption, Coactivator, Measles virus, Osteoclast, Paget's disease, Vitamin D antagonist, Vitamin D receptor",
author = "Seiichi Ishizuka and Noriyoshi Kurihara and Daishiro Miura and Kazuya Takenouchi and Jillian Cornish and Tim Cundy and Reddy, {Sakamuri V.} and Roodman, {G. David}",
year = "2004",
month = "5",
doi = "10.1016/j.jsbmb.2004.03.025",
language = "English (US)",
volume = "89-90",
pages = "331--334",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells

AU - Ishizuka, Seiichi

AU - Kurihara, Noriyoshi

AU - Miura, Daishiro

AU - Takenouchi, Kazuya

AU - Cornish, Jillian

AU - Cundy, Tim

AU - Reddy, Sakamuri V.

AU - Roodman, G. David

PY - 2004/5

Y1 - 2004/5

N2 - (23S)-25-Dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647) functions an antagonist of the 1α,25-dihydroxyvitamin D 3 (1α,25-(OH)2D3) nuclear receptor (VDR)-mediated differentiation of human leukemia (HL-60) cells [J. Biol. Chem. 274 (1999) 16392]. We examined the effect of vitamin D antagonist, TEI-9647, on osteoclast formation induced by 1α,25-(OH)2D3 from bone marrow cells of patients with Paget's disease. TEI-9647 itself never induced osteoclast formation even at 10-6 M, but dose-dependently (10-10 to 10-6 M) inhibited osteoclast formation induced by physiologic concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) from bone marrow cells of patients with Paget's disease. At the same time, 10-8 M of TEI-9647 alone did not cause 1α,25-(OH)2D3 dependent gene expression, but almost completely suppressed TAFII-17, a potential coactivator of VDR and 25-hydroxyvitamin D3-24-hydroxylase (25-OH-D3-24- hydroxylase) gene expression induced by 10-10 M 1α,25-(OH) 2D3 in bone marrow cells of patients with Paget's disease. Moreover, TEI-9647 dose-dependently inhibited bone resorption induced by 10-9 M 1α,25-(OH)2D3 by osteoclasts produced by RANKL and M-CSF treatment of measles virus nucleocapsid gene transduced bone marrow cells. These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease.

AB - (23S)-25-Dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647) functions an antagonist of the 1α,25-dihydroxyvitamin D 3 (1α,25-(OH)2D3) nuclear receptor (VDR)-mediated differentiation of human leukemia (HL-60) cells [J. Biol. Chem. 274 (1999) 16392]. We examined the effect of vitamin D antagonist, TEI-9647, on osteoclast formation induced by 1α,25-(OH)2D3 from bone marrow cells of patients with Paget's disease. TEI-9647 itself never induced osteoclast formation even at 10-6 M, but dose-dependently (10-10 to 10-6 M) inhibited osteoclast formation induced by physiologic concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) from bone marrow cells of patients with Paget's disease. At the same time, 10-8 M of TEI-9647 alone did not cause 1α,25-(OH)2D3 dependent gene expression, but almost completely suppressed TAFII-17, a potential coactivator of VDR and 25-hydroxyvitamin D3-24-hydroxylase (25-OH-D3-24- hydroxylase) gene expression induced by 10-10 M 1α,25-(OH) 2D3 in bone marrow cells of patients with Paget's disease. Moreover, TEI-9647 dose-dependently inhibited bone resorption induced by 10-9 M 1α,25-(OH)2D3 by osteoclasts produced by RANKL and M-CSF treatment of measles virus nucleocapsid gene transduced bone marrow cells. These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease.

KW - Bone resorption

KW - Coactivator

KW - Measles virus

KW - Osteoclast

KW - Paget's disease

KW - Vitamin D antagonist

KW - Vitamin D receptor

UR - http://www.scopus.com/inward/record.url?scp=3042600952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042600952&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2004.03.025

DO - 10.1016/j.jsbmb.2004.03.025

M3 - Article

VL - 89-90

SP - 331

EP - 334

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

ER -